Professor Andrew Renehan leads our research group, which engages with our research partners at The Christie NHS Foundation Trust. They include:

The Institute of Cancer Sciences at  the University of Manchester (ICS)

The Manchester Cancer Research Centre (MCRC)

Cancer Research UK Manchester Institute (CRUK-MI)

Manchester Academic Health Science Centre (MAHSC)

We have 4 research ‘pillars’


Basic laboratory science


Combining translational and clinical research, addressing questions around aetiology and the progression of the main cancers that we treat. Examples include:

  • HomeR - Development of HPV genotyping as a predictive biomarker of chemo-radiotherapy response in patients with Rectal Cancer.
  • The ENHANCE project - Deep Genotyping of HPV in Anal Cancer.
  • NORD 1 project - Establishing Methods for Evaluating Anti-tumour Therapies for Treatment of Pseudomyxoma Peritonei (PMP) using Gene Profiles and Immortalized Cells.
  • NORD 2 project - Preclinical Targeting of the Goblet Cell Differentiation Pathway in Pseudomyxoma Peritonei.

Minimal Access Surgery (MAS)

  • Surgical education research, including development and delivery of surgical oncology training programmes.
  • Evaluation of new educational tools, technologies and surgical simulations.
  • Surgical innovation and technology research, including development and evaluation of novel medical devices.
  • Pervasive healthcare and wearable technologies to improve outcomes from chemotherapy and surgery.

Clinical outcome studies/ trials and biomarker studies

  • Ongoing clinical outcome studies - in patients with anal cancer treatment, pseudomyxoma peritonei treatment, treatment for peritoneal metastases of colorectal origin, treatment for appendiceal cancer and outcomes following multi-visceral exenterative surgery.
  • Clinical trials - We aim to identify and recruit patients to clinical trials. Many of these trials are registered on the NIHR trials portfolio. Examples include ROLLAR, DREAMS, FoFACT and the upcoming national anal cancer trial, PLATO.
  • Biomarker development (blood borne and imaging) - Through the MCRC, we have a strong programme of imaging studies including L-NuANCE (Lymph Node Positivity in Patients with ANal Cancer treated in the Modern Era: prognostic impact and patterns of loco-regional relapse).

Population level studies


Professor Andrew Renehan leads the Manchester Diabetes Obesity and Cancer research group (ManDOC). They focus on untangling the complex inter-relationships between chronic disorders, like obesity and type 2 diabetes, and development of chronic diseases such as colorectal cancer. This research involves:

  • Interrogating large scale databases, such as the UK Clinical Practice Research Datalink (CPRD)
  • Advanced statistical methods
  • Bio-mathematical modelling